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Abstract
Background: Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment
pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational
studies and patient databases are often used for real-world research. However, there is limited information for each data
source on the design, consistency, data captured, limitations and usability for assessing research questions.
Using a systematic approach, we identified RWD sources for patients with retinal diseases and assessed them
for completeness of data relating to different outcomes.
Methods: A systematic literature review was carried out to identify RWD sources for patients with retinal
disease. Potentially relevant articles published between 2006 and 2016 were screened following electronic
searches in Embase and MEDLINE. Congress and supplementary searches were undertaken to identify RWD
sources that may not be referenced in full publications. For each data source, availability and quantity of data
on baseline status, clinical outcomes, treatment and management, safety, and patient-reported and economic
burden were assessed using a bespoke completeness assessment tool based on International Consortium for
Health Outcomes Measurement guidelines for macular degeneration. Completeness of data for each area of
interest in each data source was assessed and rated using a ‘good–moderate–poor’ rating system based on
availability and quantity of available data. Each data source was then given an overall score based on its
score for each of the 7 areas of interest.
Results: A total of 128 RWD sources from 32 countries were identified. Of the identified sources, 64 sources
from 16 countries of interest were analyzed. Most of these sources provided information on baseline status
and clinical outcomes and treatment, but few collected data on economic and patient-reported burden. Of
the RWD sources analyzed, 10 scored highly in the overall completeness assessment, collecting data on most
or all of the areas of interest; these sources are considered to be robust data sources for performing ophthalmology
real-world studies.
Conclusions: The study provides a comprehensive list of RWD sources for patients with retinal disease, many of which
will be useful for conducting real-world studies in the field of ophthalmology.
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Background
Retinal diseases
Retinal diseases, which are often characterized by leak-
age of fluid, hemorrhage and fibrous scarring in the
eye, include wet age-related macular degeneration
(wAMD), diabetic macular edema (DME), retinal vein
occlusion (RVO) and choroidal neovascularization
(CNV) not secondary to AMD. These diseases are
major causes of visual impairment and blindness world-
wide [1, 2]. Retinal diseases can cause irreversible loss
of visual acuity, which can have a major impact on pa-
tients’ vision-related quality of life and overall well-
being, often leading to anxiety and depression, an
increase in healthcare resource utilization and high pa-
tient support costs [3–9]. Patients commonly experi-
ence an increase in feelings of social isolation and
discontinue employment, which can, in turn, lead to a
loss of income and independence [10].
Treatment options
Over the past decade, anti-vascular endothelial growth
factor (anti-VEGF) therapy has replaced photo-
dynamic therapy and laser photocoagulation as the
standard of care for treatment of these diseases [11].
Anti-VEGF antibodies prevent the growth of new
blood vessels through inhibition of the physiological
effects of VEGF. The main anti-VEGF therapies in
current use are bevacizumab (Avastin), ranibizumab
(Lucentis) and aflibercept (Eylea). Avastin is a full-
length, recombinant, humanized, anti-VEGF monoclo-
nal antibody, which was initially designed and ap-
proved for the treatment of various solid tumors; it is
now used off-label to treat retinal disease [12–14].
Lucentis is a humanized, recombinant antibody frag-
ment of a monoclonal antibody active against all
VEGF A isoforms; it has been approved for use in
adults with wAMD, CNV, DME and RVO [15]. Eylea
is a recombinant fusion protein comprising the key
VEGF-binding domains of human VEGF receptors 1
and 2 fused to the constant region of human im-
munoglobulin G1. Eylea acts as a soluble decoy re-
ceptor that binds VEGF-A and placenta growth factor
with higher affinity than naturally occurring VEGF re-
ceptors and is approved for the treatment of wAMD,
CNV, DME and RVO [16].
Real-world data for retinal diseases
Real-world data (RWD) comprises findings from vari-
ous observational study types and can provide vital
information about the effectiveness of a treatment in
clinical practice. RWD sources consist of diverse co-
horts of patients, including those that are normally
excluded from randomized controlled trials (RCTs),
and can therefore provide insight into the clinical
effectiveness of a treatment in various subgroups of
patients in a real-world setting [17, 18]. Evidence
from RWD sources has provided a greater under-
standing of the long-term safety, effectiveness in clin-
ical practice and utilization patterns of anti-VEGF
therapy, in addition to providing important informa-
tion on the patients as well as the disease [19–21].
The use of RWD to understand retinal diseases and
current treatment options is growing. Since the approval
of the anti-VEGF therapies, many countries and regions
have set up retinal registries, observational studies and da-
tabases containing information on patients with retinal
diseases. However, the design and data captured within
these multiple data sources are not consistent, and their
usability and limitations in assessing important research
questions may not be fully understood. A valuable
addition to the scientific literature, therefore, would be a
systematic study in which all available RWD sources for
retinal diseases were identified and collated, and which
also included a qualitative assessment of the data collected
from each source. In addition, an evaluation of the
strengths and limitations of each database would be useful
to identify the most suitable RWD sources to perform fu-
ture real-world studies, and to appraise the completeness
of existing real-world studies. The objective of this study
was to conduct a systematic literature review (SLR) to
identify and compile information about existing RWD
sources that include patients with retinal diseases treated
with anti-VEGF therapies, and to assess systematically the
completeness of the data available in these sources.
Methods
The SLR was conducted in 2 stages: in the first stage,
data sources (including multinational and international
sources) outside of the USA were identified by applying
a restriction to the search terms; and, in the second
stage, a follow-up search was carried out specifically to
identify articles describing retinal disease-related data
sources within the USA.
Because this study did not involve the collection or
use of individually identifiable data, Institutional Review
Board review or approval was not required and therefore
no formal review protocol exists for this study.
Citation screening and full text review
Identified articles were screened manually based on the
title and abstract in accordance with 2009 Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [22].
Articles were eligible if they described an active RWD
source for retinal diseases (wAMD, DME, RVO and my-
opic CNV) and were published from 2006 onwards. Eli-
gible publications for all countries were tagged, but only
those for the multinational data sources and countries of
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interest were reviewed in further detail. The countries of
interest were Australia, Brazil, Canada, China, Denmark,
Finland, France, Germany, Iceland, Italy, Japan, Norway,
Spain, Sweden, the UK and the USA. Articles describing
data sources that focused on patients under 18 years of
age or patients with other retinal diseases were excluded.
Case studies, RCTs, pooled analyses, economic evalua-
tions and non-English articles were also excluded. Full-
text versions of all articles meeting the eligibility criteria
were reviewed to confirm whether the patients in the re-
ported study were recruited from an established data
source. Some data sources were described in more than
one publication.
Data extraction
Articles describing RWD sources were further ana-
lyzed to extract data on the availability of specific
variables and outcomes of interest (Table 1). General
information on each data source was extracted, such
as country, data type, patient types and numbers, and
outcomes captured. Other details relating to the own-
ership, accessibility and availability of the data source
were also recorded (Additional file 1: Table S1).
Assessing the availability and completeness of the data
collected
The variables and outcomes of interest included in the
qualitative assessment were defined based on the recom-
mendations made by the International Consortium for
Health Outcomes Measurement (ICHOM) for Macular
Degeneration (outlined by Rodrigues et al. 2016) [23].
The outcomes of interest were grouped into 7 categor-
ies: patient baseline status (patient characteristics and
baseline disease information); clinical outcomes; patient
treatment and management, including laboratory assess-
ments; anti-VEGF therapy status (naïve or experienced);
safety outcomes; patient-reported burden; and economic
burden.
Supplementary searches for each data source
For each data source, information from identified publi-
cations was supplemented by additional internet
searches for supporting resources, such as websites and
published factsheets. This approach was particularly use-
ful for gathering data source contact details and general
information.
Direct contact with data sources
It is not always possible to assess fully the suitability of
data sources because published studies may not identify
them by name, and information available on the data
source websites may be limited. Thus, we contacted the
administrators of a shortlist of identified data sources for
further information on the data collected and to assess
the accessibility of the data to external researchers. Up
to 3 attempts were made to establish contact with the
data source personnel via email or telephone. If no re-
sponse was received after the third attempt at contact,
no further action was taken to collect additional
information.
Evaluating the completeness of the data collected
To appraise the information gathered for each data
source, an assessment tool was developed that was tai-
lored to the outcomes of interest based on the ICHOM
guidelines. Using this tool, each topic of interest was
rated using a ‘good–moderate–poor’ rating system based
on the quantity and completeness of available informa-
tion for each data source (Fig. 1). For example, there
were 16 potential data points/variables related to the pa-
tient baseline status. Data sources that reported 8–16
data points were considered to be ‘good’ with regard to
baseline status, sources with 5–7 data points were classi-
fied as ‘moderate’ and sources with less than 5 data
points were classified as ‘poor’.
After the data sources were rated for each of the topics of
interest, an overall point was assigned to each to reflect its
general completeness (see Fig. 1). For each outcome of
interest, a source rated ‘good’ received 3 points, a source
rated ‘moderate’ received 2 points and a source rated ‘poor’
received 1 point. As there are a total of 7 outcomes of inter-
est, each data source could score a maximum of 21 points.
Results
Search results
In the first stage of the SLR, the electronic searches
identified 3827 articles that included information sug-
gestive of a retinal disease data source. Screening of the
full papers for data sources combined with findings from
the supplementary searches resulted in the inclusion of a
total of 119 articles referring to 89 data sources outside
the USA (Fig. 2). In the second stage, the follow-up
searches identified 1000 articles, of which 92 described
19 data sources in the USA (Fig. 2). In total, 108 RWD
sources for retinal diseases were identified in our sys-
tematic search. Supplementary searches of proprietary
databases identified 20 further data sources that were
not described in publications.
In total, the analyses identified 128 RWD sources for
retinal diseases. Of these, 6 data sources were multi-
national/international and the remaining 122 focused on a
particular country. Overall, RWD sources from 32 coun-
tries were identified (Fig. 3). Information in the non-
proprietary data sources from the countries of interest
(n = 64) was subsequently extracted from the relevant
studies (n = 212) and included in the assessment of com-
pleteness. Administrators for 42 of these data sources
were contacted by email or telephone, 8 of which
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Table 1 Completeness of data recorded in reported data sources
Country Data source name (type) Baseline
status
Outcomes
Clinical Treatment Anti-VEGF Safety Human Economic
Australia Fight Retinal Blindness (active disease registry) +++ ++ +++ +++ +++ – –
Australian Heart Eye Study (prospective cohort study) ++ – + + – – –
Blue Mountains Eye Study (prospective cohort study) +++ + + – – –
Macular Disease Foundation (active disease registry) – – + +++ – ++ –
Melbourne Collaborative Cohort Study (prospective
cohort study)
+++ – + + – – –
Canada Southwestern Ontario Database (passive disease
registry)
+++ +++ +++ +++ +++ +++ +++
British Columbia Ministry of Health Databases
(administrative/claims database)
++ – ++ +++ – – –
Quebec prescription and medical claims databases
(administrative/claims database)
++ – + – +++ – ++
China Beijing Eye Study (population-based longitudinal study) +++ +++ +++ – – – –
Denmark Four referral centres in Denmark (unnamed – electronic
medical records)
++ – + – – +++ –
France Creteil Intercommunal University Hospital Eye Clinic
(prospective cohort study)
++ +++ ++ +++ – ++ +++
Retina France (cross-sectional study) +++ – ++ +++ – +++ +++
ALIENOR (prospective cohort study) +++ + +++ + – +++ –
Germany OCEAN (prospective cohort study) ++ +++ +++ +++ – +++ ++
CAPTAIN (retrospective cohort study) +++ – +++ +++ – ++ +++
Bonn Ophthalmology online network (active
disease registry)
+ ++ ++ +++ – – +++
Gutenberg Health Study (prospective cohort study) +++ +++ + + – – –
FAM study (prospective cohort study) +++ – ++ + – – –
Landschaftsverband Rheinland database (active disease
registry)
++ – – + – – –
Iceland Age, Gene/Environment Susceptibility–Reykjavik Study
(prospective cohort study)
+++ – – + – – –
Japan Japan Medical Data Centre (administrative/claims
database)
++ – ++ +++ – – +++
Hatoyama Cohort Study (prospective cohort study) +++ – + – – ++ ++
Hisayama study (prospective cohort study) ++ – + + – – –
Multinational AURA study +++ +++ +++ +++ +++ – +++
The EPICOHORT study ++ +++ +++ +++ +++ – –
European Genetics Database +++ +++ +++ +++ – – ++
IRISS + ++ + – +++ – –
LUMINOUS study ++ +++ +++ +++ +++ – +++
VigiBase +++ ++ ++ +++ +++ – –
Norway Tromso Eye Study (population-based longitudinal
study)
+++ – + + – – –
Sweden Swedish Macula Register (active disease registry) +++ +++ +++ +++ +++ +++ +++
Swedish Lucentis Quality Registry (active disease
registry)
++ +++ +++ +++ +++ +++ ++
UK British Ophthalmological Surveillance Unit (electronic
medical records)
++ ++ +++ +++ +++ – +++
Medisoft (electronic medical records) +++ +++ +++ +++ +++ +++ +++
Scotland intravitreal ranibizumab treatment register (unnamed +++ +++ +++ +++ +++ – +++
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Table 1 Completeness of data recorded in reported data sources (Continued)
Country Data source name (type) Baseline
status
Outcomes
Clinical Treatment Anti-VEGF Safety Human Economic
– electronic medical records)
UK Age-Related Macular Degeneration Electronic
Medical Record Users Group (retrospective cohort
study)
++ +++ +++ +++ +++ – +++
Unnamed tertiary referral clinic (active disease registry) +++ +++ +++ +++ – – +++
Gloucestershire NHS ophthalmology department
(electronic medical records)
++ +++ +++ +++ – – –
Medical Retina Clinic at King’s College London
(electronic medical records)
+++ +++ +++ +++ – – ++
Medical Retina Service, St Thomas’ Hospital (electronic
medical records)
++ +++ ++ +++ – – +++
Belfast Health and Social Care Trust database (unnamed
- electronic medical records)
++ – ++ +++ +++ – –
The National Ophthalmology Database (active disease
registry)
++ – – + – – –
Grampian University Hospitals (electronic medical
records)
++ – – + – – –
English National Hospital Episode Statistics (electronic
medical records)
++ – – – – – –
USA Duke University Eye Center (active disease registry) +++ +++ +++ +++ +++ +++ ++
Bascom Palmer Eye Institute (active disease registry) ++ +++ +++ +++ +++ – –
IMS Health (administrative/claims database) ++ – +++ +++ +++ – +++
Wilmer Eye Institute (electronic medical records) ++ +++ +++ +++ +++ – –
Doheny Eye Institute (active disease registry) +++ +++ +++ +++ – – –
VRMNY (electronic medical records) +++ +++ +++ +++ – – –
Wills Eye Hospital (electronic medical records) +++ +++ +++ +++ – – –
A2ASDOCT (prospective observational study) +++ +++ +++ – – – –
Shiley Eye Center (prospective observational study) ++ +++ +++ +++ – ++ ++
BRFSS (questionnaire/survey) +++ – + – – ++ ++
i3 InVision Data Mart (electronic medical records) +++ – ++ +++ – – –
New England Eye Center (retrospective observational
study)
++ +++ +++ – – – –
SOF/IAMD (prospective observational study) +++ +++ + + – – –
Beaver Dam Eye Study (prospective observational
study)
+++ +++ + – – – –
LALES (prospective observational study) +++ – + – – +++ –
Nurses’ Health Study (prospective observational study) +++ – ++ + – – –
CAREDS (prospective observational study) +++ – + – – – –
MESA +++ – + – – – –
NHANES +++ – + – – – –
+++, ‘good’; ++. ‘moderate’; +, ‘poor’; −, ‘unknown’. A2ASDOCT, AREDS (Age-Related Eye Disease Study) 2 Ancillary Spectral Domain Optical Coherence
Tomography Study; ALIENOR, Antioxydants, LIpides Essentiels, Nutrition et maladies OculaiRes; AURA, Study to Assess the Effectiveness of Existing Anti vascular
Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration; BRFSS, Behavioral Risk Factor Surveillance System; CAPTAIN, the
comparison of applied ophthalmological tests for suspected age-related macular disease patients; CAREDS, Carotenoids in Age-Related Eye Disease Study;
EPICOHORT, study to assess the safety profile, treatment patterns, and efficacy of ranibizumab in real-life clinical setting/routine clinical practice; FAM, Fundus
Autofluorescence in Age-related Macular Degeneration Study; IMS Health, IMS Health Real-World Data Medical Claims database; IRISS, The ILUVIEN Registry Safety
Study; LALES, Los Angeles Latino Eye Study; LUMINOUS, study to evaluate the long-term safety, efficacy, treatment patterns and health-related quality of life
outcomes in patients treated with ranibizumab in routine practice; MESA, Multiethnic Study of Atherosclerosis; NHANES, US National Health and Nutrition
Examination Survey; NHS, UK National Health Service; OCEAN, Observation of Treatment Patterns With Lucentis in Approved Indications; SOF/IAMD, Study of
Osteoporotic Fractures/Incidence of AMD study; UK, United Kingdom; UK-AMD-EMR, UK Age-Related Macular Degeneration Electronic Medical Record Users
Group; USA, United States of America; VEGF, vascular endothelial growth factor; VRMNY, Vitreous Retina Macula Consultants of New York
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Fig. 1 Data source completeness assessment criteria. *Outcomes data received through direct contact were classified as good if the data source
administrator confirmed its availability. BCVA, best-corrected visual acuity; IVIS, Impact of Visual Impairment Scale; VEGF, vascular endothelial
growth factor; VFQ-25, 25-item Visual Function Questionnaire
Fig. 2 PRISMA diagram. *Countries of interest: Australia, Brazil, Canada, China, Denmark, Finland, France, Germany, Iceland, Italy, Japan, Norway,
Spain, Sweden, the UK and the USA. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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responded positively to a request for information: National
Ophthalmology Database (UK); Australian Heart Eye
Study; Southwestern Ontario Database (Canada);
English National Hospital Episode Statistics (UK); Japan
Medical Data Center; World Health Organization Data-
base of Adverse Drug Reactions; Swedish Macula Regis-
ter; and the Medical Retina Service in St Thomas’
Hospital (UK). The data already extracted for these
sources were supplemented with the information
received from direct contact.
Data source characteristics
Among the 64 data sources included for extraction and
assessment, 33 were referred to in 1 or 2 publications.
The multinational LUMINOUS program and the
Beaver Dam Eye Study in the USA were the most
widely cited data sources, referred to in 15 and 17 pub-
lications, respectively (Fig. 4). The USA had the highest
number of RWD sources with 19, followed by 13 for
the UK and 6 for Germany. The most common types of
RWD sources were prospective cohort studies (n = 21),
electronic medical records (n = 14) and active disease
registries (in which data are collected as ‘policy’,
n = 14). The other identified data sources were adminis-
trative/claims databases (n = 4), retrospective cohort
studies (n = 4), population-based longitudinal studies
(n = 2), passive disease registries (in which data are
collected upon recommendation or out of interest; n =
2), surveys (n = 2) and a cross-sectional study (n = 1).
The identified data sources varied widely in terms of num-
bers of patients included. Two data sources included in-
formation for less than 100 patients and an additional 2
data sources included data for more than 100,000 patients.
The Japan Medical Data Center had information on more
than 700,000 patients with AMD, the largest number of
relevant patients in a single database, followed by the
Nurses’ Health Study (USA) with more than 280,000 par-
ticipants. However, the IMS Health Real-World Data
Medical Claims database (USA) contained the highest cu-
mulative number of patients, with about 1 billion profes-
sional fee claims per year. The i3 InVision Data Mart
(USA) included data from more than 15 million annual
lives and Wills Eye Hospital (USA) included data from
more than 250,000 patients each year.
Outcomes reported and assessment of completeness
Overall, there was significant heterogeneity in outcomes
collected between registries, with the majority of RWD
sources providing information on patient baseline status,
clinical outcomes and treatment outcomes (Fig. 5). All but
1 of the analyzed data sources recorded information on
patient baseline status (patient characteristics and baseline
disease information: 98% [63/64]); the majority included
Fig. 3 Geographical distribution of identified data sources*. Countries with identified data sources: Australia, Barbados, Belgium, Canada, China,
Croatia, Czech Republic, Germany, Denmark, France, Greece, Iceland, India, Iran, Israel, Japan, Malaysia, The Netherlands, New Zealand, Nigeria,
Norway, Poland, Portugal, Republic of Ireland, Singapore, South Korea, Sweden, Switzerland, Taiwan, Thailand, Turkey, the UK and the USA. * This
is an original image created by the authors
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‘good’ or ‘moderate’ data on baseline status (97% [61/63]).
Most data sources collected information on patient age
(60/64) and sex (61/64), but less than half collected infor-
mation on ethnicity (28/64), smoking status (24/64) and
cardiovascular measurements (28/64). Regarding baseline
clinical status, distance visual acuity at baseline was
recorded in two-thirds of identified data sources (68% [44/
64]). Many of the data sources also recorded geographic
atrophy (25/64), subretinal fibrosis (20/64), pigment
epithelial detachment (24/64) and ocular comorbidities
Fig. 5 Completeness of identified data sources. VEGF, vascular endothelial growth factor
Fig. 4 Number of publications per data source*. A2ASDOCT, AREDS (Age-Related Eye Disease Study) 2 Ancillary Spectral Domain Optical
Coherence Tomography Study; BES, Beijing Eye Study; BMES, Blue Mountains Eye Study; LALES, Los Angeles Latino Eye Study; LUMINOUS, study
to evaluate the long-term safety, efficacy, treatment patterns and health-related quality of life outcomes in patients treated with ranibizumab in
routine practice; MCCS, Melbourne Collaborative Cohort Study; MESA, Multiethnic Study of Atherosclerosis; VRMNY, Vitreous Retina Macula
Consultants of New York. * Data sources with more than 5 relevant publications
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(25/64), and around a third recorded previous treatment
information (34% [22/64]).
Around half of the analyzed data sources (56% [34/64])
recorded data on clinical outcomes (best-corrected visual
acuity [BCVA]), most of which also reported the method
of BCVA assessment (79% [27/34]). All of the data sources
recorded BCVA using the Early Treatment of Diabetic
Retinopathy Study protocol, Snellen chart or the logMAR
chart (where visual acuity is scored with reference to the
logarithm of the minimum angle of resolution). Data on
patient treatment, including laboratory assessments, were
available in most sources (90% [58/64]). For treatment
data, 60% of data sources (39/64) recorded treatments re-
ceived, most of which included information on anti-VEGF
therapy (92% [36/39]). Further treatment data, such as fre-
quency of treatment, duration of treatment and cause of
treatment discontinuation, were recorded in 12, 11 and 5
of these data sources, respectively. Safety outcomes, in-
cluding ocular and non-ocular adverse events, were re-
ported in few data sources (30% [19/64]); most of these
(16/19) recorded ocular adverse events, including endoph-
thalmitis, hemorrhage and corneal abrasion.
When assessing the availability of patient-reported
burden outcomes, quality-of-life data were available in a
quarter of identified data sources (25% [16/64]). Of
these, 7/16 assessed vision-related quality of life using
the 25-item Visual Function Questionnaire. The
remaining data sources used other instruments, includ-
ing: the Geriatric Depression Scale short form, with 15
items; the basic Activities of Daily Living scale, with 5
items; and the social function questionnaire in the
Hatoyama Cohort Study. Economic burden data were
collected in 41% (27/64) of the identified data sources.
More than half of these 27 sources recorded the number
of injections (22/27) or number of visits (17/27).
Overall, 10 data sources scored well across the differ-
ent variables, gaining at least 16 points out of a possible
total of 21. These 10 sources are considered to be ro-
bust data sources for performing ophthalmology real-
world studies looking at 5 or more of the 7 outcomes
of interest. The top 10 data sources identified were:
Southwestern Ontario Database (Canada; 21 points);
Swedish Macula Register (21 points); Medisoft (UK; 21
points); Duke University Eye Centre (USA; 20 points);
the Swedish Lucentis Quality Registry (19 points); the
Study to Assess the Effectiveness of Existing Anti vas-
cular Endothelial Growth Factor (anti VEGF) in Pa-
tients With Wet Age-related Macular Degeneration
(AURA study; multinational; 18 points); an unnamed
ranibizumab treatment register in south-east Scotland
(UK; 18 points); the LUMINOUS program (multi-
national; 17 points); the UK Age-Related Macular De-
generation Electronic Medical Record System Users
Group (17 points); and the Observation of Treatment
Patterns With Lucentis in Approved Indications
(OCEAN study; Germany; 16 points).
Discussion
Summary of the findings
To our knowledge, this is the first study to identify and
evaluate systematically the completeness of retinal
disease-related RWD sources. Our study identified many
sources of RWD that provide insightful and comprehen-
sive evidence on retinal diseases and their treatments. Of
the 128 data sources identified, 64 were analyzed in de-
tail, 10 of which were considered to be useful sources
for carrying out real-world studies for most or all of the
outcomes of interest, including patient information, clin-
ical and safety outcomes, treatment information, and
patient-reported and economic burden.
Value of real-world evidence in ophthalmology
RWD provides information about the effectiveness of a
treatment in a real-life setting in a wider patient popu-
lation than in a RCT. RWD adds to the evidence base
for a disease and its treatment by providing information
on topics such as long-term safety, treatment patterns,
disease progression and burden of illness, which are not
designed to be assessed in clinical trials. RWD are in-
creasingly being considered alongside data from RCTs
in healthcare decision-making. For instance, the US
Food and Drug Administration uses RWD in specific
contexts (for example, with devices) based on existing
evidentiary standards. Similarly, the National Institute
for Health and Care Excellence (NICE) in the UK con-
siders RWD in addition to more traditional clinical evi-
dence in technology appraisals. Therefore, robust data
sources that permit high-quality, observational research
on outcomes of interest are important to meet the in-
creasing demands for real-world evidence from health-
care decision-makers. Among the data sources analyzed
in this study, we confirmed that the Southwestern On-
tario Database (Canada), the Swedish Macula Register
and Medisoft (UK) record data on all outcomes of
interest as recommended by the ICHOM guidelines,
each scoring the full 21 points. As such, these 3 RWD
sources will be useful for developing comprehensive
real-world studies.
Characteristics of data sources identified
RWD have provided important insights in the ophthal-
mology field, particularly in terms of treatment outcomes
for anti-VEGF regimens, by permitting the assessment of
outcomes for patients who may not typically be included
in RCTs. Our study identified that there are many
sources of RWD for retinal diseases and treatments
worldwide. A high proportion of the sources recorded
data on patient treatment and management (90% [58/
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64]), with 60% of these sources capturing information on
whether or not patients had received anti-VEGF therapy.
In addition to treatment information, many of the data
sources provided information on the patient and their
disease characteristics, as well as clinical outcomes. In
contrast, relatively few data sources collected safety out-
comes, patient-reported burden and economic data. In
total, 10 data sources (6 from Europe, 1 from Canada, 2
multinational and 1 from the USA) provide good or
moderate data for multiple outcomes of interest. It is im-
portant for retinal data sources to measure multiple out-
comes to be able to provide a true sense of treatment
effectiveness in clinical practice; measuring visual acuity,
for example, is meaningless without capturing informa-
tion on treatment patterns. By providing comprehensive
information on clinical, treatment, safety, human and
economic outcomes, these data sources can be consid-
ered to be robust for performing real-world studies.
Outcomes assessed
To assess the completeness of the identified data
sources, data items for outcomes of interest were se-
lected and sources were scored on the presence or com-
pleteness of the data captured. For some outcomes of
interest, our study found that the type and depth of in-
formation available differed across the data sources. This
might reflect differences in how the data are captured
and/or reported in publications. To permit comparison
across real-world sources, it is important to standardize
the types of data items collected and the outcome defini-
tions used. In addition, the most suitable and relevant
data items should be captured. Data items collected for
appraisal of the data sources in this study were based on
recommendations by the ICHOM guidelines, as outlined
by Rodrigues et al. (2016) [23]. The data items collected
in the completeness assessment in our study is based on
recommendations for outcomes that matter most to pa-
tients and which therefore can be considered as robust
data items for assessment [23]. Although many RWD
sources capture the data items recommended by the
ICHOM guidelines, this study has highlighted that sev-
eral sources omit key outcomes measures. Therefore,
there is a need for new RWD sources that standardize
and align the data collected.
Strengths and limitations
This is the first analysis to identify and assess all world-
wide RWD sources for patients with retinal disease
treated with anti-VEGF therapy. This analysis used a ro-
bust and systematic approach to identify all the data
sources available, and collected data items that were rec-
ommended in the ICHOM guidelines. The completeness
assessment profile for each data source was based on
previously published methodology for a similar study
assessing the location and quality of renal registries [24].
A systematic review of electronic literature databases
was performed to identify the relevant data sources. It is
possible that our analysis may have missed some data
sources, although we did perform online searches of
congresses and other websites, as well as conducting
searches for proprietary data sources to identify any fur-
ther sources that may not have been included in peer-
review articles. Our searches were performed up until
July 2016, so any data sources published after this date
are not included in this analysis. At the time of the
searches, the American Academy of Ophthalmology In-
telligent Research in Sight (IRIS) registry had limited
publications; as a result, this data source has not been
highlighted in this study.
The bespoke grading system for data sources illus-
trates the breadth and type of data collected within each
outcome of interest, but our study did not assess the
data sources in terms of how the data are collected, the
quality-check mechanisms in place, or how closely the
data items collected compare with those recommended
by the ICHOM guidelines. The assessment of the data
sources may have been influenced by the amount of data
available for a particular data source; for example, a
source may have been graded 'poor' or 'unknown' for a
particular outcome if retinal disease-related data from
the source remains unpublished. For several of the data
sources, we contacted the administrators to obtain fur-
ther information that may not have been in the public
domain to enable us to provide the most comprehensive
assessment possible of these data sources. However, to
limit the scope of the project, contacts were only pur-
sued for a subset of the data sources. In addition, the
completeness assessment was only undertaken for the
multinational/international data sources, or sources from
a shortlist of countries of interest. Therefore, the find-
ings of this study should be interpreted with caution, as
they are mostly relevant to international data sources or
those from countries with published data. As a follow-
up to this analysis, all the data sources identified in this
SLR, including the proprietary data sources, could be
assessed for their completeness.
Conclusions
This study provides a comprehensive list of worldwide
RWD sources for patients with retinal diseases treated
with anti-VEGF therapies. Here, we show that there are
many sources providing comprehensive data that can be
used to conduct real-world studies. Although the
sources vary in types of data items collected and the
methods of data collection used, many of the RWD
sources collect patient-relevant outcomes that provide
important evidence in the field of ophthalmology.
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Method of literature search
RWD sources for patients with retinal diseases treated with
anti-VEGF therapies were identified through an SLR. The
SLR focused on searches using the electronic literature data-
bases Embase (Elsevier) and MEDLINE (Ovid platform
[Wolters-Kluwer], including MEDLINE In-Process & Other
Non-Indexed Citations); the aim was to identify relevant ar-
ticles describing RWD sources for retinal diseases, such as
patient registries, hospital and insurance claims databases,
electronic medical records, longitudinal and observational
studies, as well as population-based surveys. The SLR was
conducted in 2 stages: in the first stage, data sources (includ-
ing multinational and international sources) outside of the
USA were identified by applying a restriction to the search
terms. The electronic search for the first stage was carried
out in July 2016. In the second stage, a follow-up search was
carried out in March 2017 specifically to identify articles de-
scribing retinal disease-related data sources within the USA.
In addition to searching the electronic literature data-
bases, the following congress websites were used to identify
relevant abstracts and posters published between 2012 and
2016: The International Society for Pharmacoeconomic
Outcomes Research (ISPOR) European congress, Associ-
ation of Research in Vision and Ophthalmology, World
Ophthalmology Congress, European Society of Retina Spe-
cialists, Asia Pacific Vitreo-retina Society, and American
Academy of Ophthalmology. Additional searches to identify
country-specific RWD sources were conducted of clinical
trial websites (clinicaltrials.gov and eudract.ema.europa.eu)
and the World Health Organization registry list, as well as
using the Google and Google Scholar search engines. To
limit the scope of the study, the supplementary searches fo-
cused on only a restricted number of countries (Australia,
Brazil, Canada, China, Denmark, Finland, France, Germany,
Iceland, Italy, Japan, Norway, Spain, Sweden and the UK).
To identify large, proprietary databases that may not be
referenced in publications, a grey literature search was con-
ducted of the ISPOR website for both a list of databases and
a list of vendors who may provide access to RWD sources.
A Google search of RWD terms (such as ‘real-world data’,
‘real-world evidence’, ‘RWE’, etc.) was also undertaken.
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